UPA Tesamorelin 2mg | Platinum Series | GHRH Peptide

• Brand: UPA / Ultimate Precision Anabolics
• Series: Platinum Series
• Compound: Tesamorelin
• Class: Growth Hormone-Releasing Factor analogue
• Vial: 2 mg lyophilized powder
• Presentation: Vial + 2 mL bacteriostatic water shown in supplied packaging
• Research focus: GH/IGF-1 signalling, endocrine physiology and body composition
• Product format: Lyophilized peptide
• Storage shown by UPA: 2–8°C for the lyophilized product/refrigerated handling information 

Research Reference — Laboratory Use Only

Experimental concentration ranges, study duration, sample preparation and analytical procedures should be determined according to the relevant research protocol, institutional requirements and applicable scientific literature.

No human dosing, administration or treatment protocol is provided on this product page.

For pharmaceutical reference purposes, dosing information should be obtained from the relevant approved prescribing information rather than extrapolated from this UPA research product. The FDA's current EGRIFTA WR label is specific to its approved formulation and indication. 

What is UPA Tesamorelin 2mg?

UPA Tesamorelin 2mg is a lyophilized tesamorelin peptide product from UPA's Platinum Series. UPA identifies tesamorelin as a GHRH/GHRF peptide. 

What is tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing factor that stimulates the growth-hormone pathway.

What does tesamorelin research focus on?

Research commonly focuses on GH secretion, IGF-1 regulation, endocrine signalling, adipose tissue and body-composition physiology.

Is tesamorelin a growth hormone?

No. Tesamorelin is not growth hormone itself. It is a growth hormone-releasing factor analogue that acts upstream of growth hormone secretion. 

What is the strength of the UPA vial?

The UPA product is presented as a 2 mg lyophilized vial. 

What comes with the product?

The supplied packaging shows one 2 mg tesamorelin vial and one 2 mL bacteriostatic-water ampoule. 

Is tesamorelin approved for weight loss?

The FDA label for EGRIFTA WR states that tesamorelin is indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy and specifically states that it is not indicated for weight-loss management. 

Does tesamorelin affect IGF-1?

Yes. FDA prescribing information states that tesamorelin stimulates growth hormone production and increases serum IGF-1. 

What research areas are relevant to tesamorelin?

Relevant areas include endocrine physiology, GH/IGF-1 signalling, adipose-tissue research, metabolic research and peptide pharmacology.

Does the UPA product have the same formulation as EGRIFTA?

Not necessarily. An approved pharmaceutical product and a research-market product should not be assumed to have identical formulation, excipients, manufacturing controls or regulatory status simply because they contain the same active compound.

Is tesamorelin suitable for everyone?

Clinical tesamorelin products have specific contraindications and warnings. The FDA label includes considerations involving active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy, elevated IGF-1 and glucose intolerance. 

How should the product's identity and purity be assessed?

Batch-specific analytical documentation and appropriate laboratory testing should be used to verify identity, purity and concentration rather than relying solely on packaging claims.

Tesamorelin is a synthetic analogue of growth hormone-releasing factor that acts on the pituitary growth-hormone pathway. Clinical and pharmacological research has examined its effects on growth hormone secretion, IGF-1 concentrations and adipose-tissue distribution.

The strongest clinical evidence relates to excess abdominal fat associated with HIV-related lipodystrophy. FDA prescribing information describes tesamorelin as a GHRF analogue and identifies reduction of excess abdominal fat in HIV-infected adults with lipodystrophy as the approved indication for EGRIFTA WR. The same label explicitly states that it is not indicated for weight-loss management. 

Tesamorelin research also provides a useful model for studying the interaction between GHRH signalling, growth hormone secretion, IGF-1 and adipose-tissue physiology.